Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 391

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 391
---
 $         |  10.00 |     |             | 9.68 |

The intrinsic value of Predecessor
options exercised during the year ended December 31, 2023 was $. No options were exercised in the Successor period from February
14, 2024 to December 31, 2024.

On March 25, 2024, the stockholders approved the CERo Therapeutics
Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and 2024 Employee Stock Purchase Plan (“2024 ESPP”),
with an initial reserve of and shares of common stock, respectively. The 2024 Plan and 2024 ESPP became effective on February
14, 2024 in connection with the closing of the Business Combination. At a special meeting of stockholders on April 30, 2024, the stockholders
approved an increase in the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant
to incentive stock options, by an additional shares each. At a special meeting of stockholders on November 11, 2024, the stockholders
approved an increase in the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant
to incentive stock options, by an additional shares each. As of December 31, 2024, no awards have been granted under the 2024
ESPP. The 2024 Plan has an evergreen provision that allows for an annual increase in the number of shares available for issuance under
the 2024 Plan to be added on the first day of January, starting with January 1, 2025, in an amount equal to the lesser of (i) % of the
fully diluted shares of our Common Stock on the immediately preceding December 31 or (ii) such number of shares as determined by our board
in each case subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. On January 1,
2025, the number of shares reserved under the 2024 Plan was increased by % of the fully diluted shares of our common stock on the immediately
preceding December 31, or shares. The 2024 ESPP has an evergreen provision that allows for an annual increase in the number of
shares available for issuance under the 2024 ESPP to be added on the first day of